SAGE Jan 2026 7.500 call
| Previous Close | 2.9600 |
| Open | 2.7500 |
| Bid | 2.0000 |
| Ask | 2.9500 |
| Strike | 7.50 |
| Expire Date | 2026-01-16 |
| Day's Range | 2.7500 - 3.0000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 7 |
ZacksSAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
Sage Therapeutics announces discontinuation of the collaboration agreement with Biogen related to SAGE-324 for essential tremor.
Business WireSage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
CAMBRIDGE, Mass., September 26, 2024--Sage Therapeutics, Inc. (NASDAQ: Sage) today announced that Biogen has terminated its rights under the collaboration and license agreement with Sage specific to the SAGE-324 program. The companies recently announced negative results from the Phase 2 KINETIC 2 Study of investigational SAGE-324 for the chronic treatment of essential tremor (ET) and discontinued further clinical development of SAGE-324 in ET.
Insider MonkeySage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers
We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Sage Therapeutics, Inc. (NASDAQ:SAGE) stands against the other worst 52-week low stocks to buy now according to short sellers. The U.S. Federal Reserve conducting a […]
